267 related articles for article (PubMed ID: 19053209)
41. Immunotherapeutics in development for prostate cancer.
Harzstark AL; Small EJ
Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
[TBL] [Abstract][Full Text] [Related]
42. Strategies used for MUC1 immunotherapy: human clinical studies.
Tang CK; Katsara M; Apostolopoulos V
Expert Rev Vaccines; 2008 Sep; 7(7):963-75. PubMed ID: 18767946
[TBL] [Abstract][Full Text] [Related]
43. Targeting Angiogenesis With Peptide Vaccines.
Rahat MA
Front Immunol; 2019; 10():1924. PubMed ID: 31440262
[TBL] [Abstract][Full Text] [Related]
44. Advances in immunotherapy for pancreatic cancer: 2013.
DeVito NC; Saif MW
JOP; 2013 Jul; 14(4):347-53. PubMed ID: 23846925
[TBL] [Abstract][Full Text] [Related]
45. Designing therapeutic cancer vaccines by mimicking viral infections.
Sultan H; Fesenkova VI; Addis D; Fan AE; Kumai T; Wu J; Salazar AM; Celis E
Cancer Immunol Immunother; 2017 Feb; 66(2):203-213. PubMed ID: 27052572
[TBL] [Abstract][Full Text] [Related]
46. Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.
Harao M; Mittendorf EA; Radvanyi LG
BioDrugs; 2015 Feb; 29(1):15-30. PubMed ID: 25523015
[TBL] [Abstract][Full Text] [Related]
47. Development of tumour peptide vaccines: From universalization to personalization.
Ma M; Liu J; Jin S; Wang L
Scand J Immunol; 2020 Jun; 91(6):e12875. PubMed ID: 32090366
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic human papillomavirus vaccination.
Albers AE; Kaufmann AM
Public Health Genomics; 2009; 12(5-6):331-42. PubMed ID: 19684445
[TBL] [Abstract][Full Text] [Related]
49. GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers.
Nava-Parada P; Emens LA
Curr Opin Mol Ther; 2007 Oct; 9(5):490-7. PubMed ID: 17932813
[TBL] [Abstract][Full Text] [Related]
50. Current developments with peptide-based human tumor vaccines.
Khazaie K; Bonertz A; Beckhove P
Curr Opin Oncol; 2009 Nov; 21(6):524-30. PubMed ID: 19770763
[TBL] [Abstract][Full Text] [Related]
51. Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction.
Mills KH
Immunol Lett; 2009 Feb; 122(2):108-11. PubMed ID: 19100777
[TBL] [Abstract][Full Text] [Related]
52. Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer.
Talebian Yazdi M; Keene KR; Hiemstra PS; van der Burg SH
Expert Rev Vaccines; 2014 Jan; 13(1):87-116. PubMed ID: 24308580
[TBL] [Abstract][Full Text] [Related]
53. Peptide-Based Cancer Vaccine Strategies and Clinical Results.
Schneble E; Clifton GT; Hale DF; Peoples GE
Methods Mol Biol; 2016; 1403():797-817. PubMed ID: 27076168
[TBL] [Abstract][Full Text] [Related]
54. Peptide vaccines for hepatocellular carcinoma.
Nobuoka D; Yoshikawa T; Sawada Y; Fujiwara T; Nakatsura T
Hum Vaccin Immunother; 2013 Jan; 9(1):210-2. PubMed ID: 23442593
[TBL] [Abstract][Full Text] [Related]
55. Cancer vaccines. Any future?
Myc LA; Gamian A; Myc A
Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
[TBL] [Abstract][Full Text] [Related]
56. Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients.
Victora GD; Socorro-Silva A; Volsi EC; Abdallah K; Lima FD; Smith RB; Moyses RA; Zárate-Bladés CR; Michaluart P; Silva CL; Kalil J; Coelho V
Cancer Gene Ther; 2009 Jul; 16(7):598-608. PubMed ID: 19197326
[TBL] [Abstract][Full Text] [Related]
57. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy.
Beebe M; Qin M; Moi M; Wu S; Heiati H; Walker L; Newman M; Fikes J; Ishioka GY
Hum Vaccin; 2008; 4(3):210-8. PubMed ID: 18382135
[TBL] [Abstract][Full Text] [Related]
58. Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine.
Adotévi O; Dosset M; Galaine J; Beziaud L; Godet Y; Borg C
Hum Vaccin Immunother; 2013 May; 9(5):1073-7. PubMed ID: 23357860
[TBL] [Abstract][Full Text] [Related]
59. Tumour vaccine approaches for CNS malignancies: progress to date.
Ebben JD; Rocque BG; Kuo JS
Drugs; 2009; 69(3):241-9. PubMed ID: 19275269
[TBL] [Abstract][Full Text] [Related]
60. The biological basis for immunotherapy in patients with chronic myelogenous leukemia.
Pinilla-Ibarz J; Shah B; Dubovsky JA
Cancer Control; 2009 Apr; 16(2):141-52. PubMed ID: 19337200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
